Evidence map›Paper›PMID 32955801›Full record

ArticleJournal of evaluation in clinical practice2020

Hydroxychloroquine for prophylaxis of COVID-19 physicians survey: Despite lack of evidence, many would take or give to dear ones, and despite the perceived necessity of an RCT, few would participate.

Cristian Baicus, Larisa Pinte, Laura E Stoichitoiu, Camelia Badea

Open access · bronzeAbstract read
In one paragraph

Article in Journal of evaluation in clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hydroxychloroquine/Chloroquine Prophylaxis among Health-care Workers: Was it Really Preventive? - Evidence from a Multicentric Cross-sectional Study.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Cristian BaicusDepartment of Internal Medicine, Colentina Hospital, Bucharest, Romania.
Larisa PinteDepartment of Internal Medicine, Colentina Hospital, Bucharest, Romania.
Laura E StoichitoiuDepartment of Internal Medicine, Colentina Hospital, Bucharest, Romania.ORCID 0000-0002-0234-0856
Camelia BadeaDepartment of Internal Medicine, Colentina Hospital, Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROSpitalul Clinic Colentina · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere was no evidence concerning the prophylaxis with hydroxychloroquine, and only low-grade evidence regarding the use of hydroxychloroquine as a treatment for COVID-19 patients. We performed a survey among Romanian physicians in order to see how many of them would administer prophylactically hydroxychloroquine to themselves or to people close to them, and if they would participate to a randomized controlled trial.

methodsBetween March 30 and April 02, 2020, a 16-item questionnaire was shared in a Romanian Facebook group of 2645 physicians dedicated to COVID-19 information, asking to be completed by physicians who could be directly involved in the care of these patients.

resultsA total of 785 answers were collected. Nine physicians (1.1%) thought that there was clear evidence on prescribing hydroxychloroquine prophylaxis, 375 (48%) considered the evidence acceptable, 348 (44.3%) considered it weak, whereas 53 (6.8%) answered there was no evidence. 59 (7.5%) respondents were determined to take it (of which 31 = 4% already took), 192 (24.5%) were inclined to take, 271 (34.5%) were not decided yet. 175 (22.3%) of respondents declared they (would) give the treatment to their close ones, and this decision was associated with a higher age (P = 0.003), and the opinion that there was evidence (P < 0.001). When asked about the source of the treatment regimen, 286 (36.4%) indicated a scientific paper, while no scientific paper about the prophylaxis with hydroxychloroquine existed at that time. 718 (91.5%) considered a randomized clinical trial necessary (RCT), but only 333 (42.4%) answered they would enrol in such a trial. There was only a very weak correlation (Kendall's tau _b = 0.255, P < 0.001) between the belief that an RCT is necessary and the willingness to enrol in such an RCT.

conclusionsDespite the lack of evidence, many physicians considered the evidence as existing, and were ready to take or to give hydroxychloroquine prophylactically to family. They considered an RCT necessary, but they were not willing to participate.

Indexed as

COVID-19 Drug TreatmentAntiviral AgentsAttitude of Health PersonnelClinical CompetenceCOVID-19Family PracticeHumansHydroxychloroquineInappropriate PrescribingPractice Patterns, Physicians'Pre-Exposure ProphylaxisRomaniaAntiviral AgentsHydroxychloroquineCOVID-19hydroxychloroquinephysiciansprophylaxisrandomized controlled trialsurvey

Identifiers

PMID32955801
PMCPMC7537297
OpenAlexW3087070225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.